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OBJECTIVES: The Nplate® NEXUS (NEXUS) Program included a registry of patients
in theUnited States tomonitor the long-termsafety and assure safe use ofNplate®.
Adverse events of special interest include changes in bone marrow reticulin for-
mation and collagen fibrosis, worsened thrombocytopenia after cessation of
Nplate®, thrombotic/thromboembolic complications, new hematologic malignan-
cies and progression of malignancy in patients with pre-existing hematological
malignancies or myelodysplastic syndromes (MDS), and medication errors associ-
ated with serious outcomes. METHODS: Data were collected through structured
questionnaires completed by healthcare professionals registered for the NEXUS
Program at baseline and every 6 months thereafter. RESULTS: Between August 22,
2008 and January 31, 2011, 5,235 patients (51% female, mean age 62 years, median
baseline platelet count 20x109/L) had enrolled in the NEXUS Program and received
Nplate®. The reported diagnoses were ITP (88.3%), other (8.9%), thrombocytopenia
from hematologic or lymphatic malignancies (1.1%), MDS (1.0%), and thrombocy-
topenia from chemotherapy (0.6%). Before entry, 86.1% of patients had received ITP
therapies, most commonly corticosteroids (61.8%), IVIG (55.4%), and rituximab
(42.5%). At baseline, 62.9% of patients were receiving concurrent ITP therapy, in-
cluding corticosteroids (43.8%), IVIG (17.7%), and rituximab (11.4%). Prior to enroll-
ment, 24.7% of patients had a splenectomy. As of December 2011, the FDA and
Amgen concluded that the restricted elements of the REMS could be eliminated.
CONCLUSIONS: The majority of patients in the NEXUS Program receiving Nplate®
were reported to have an ITP diagnosis with a history of previous ITP therapies and
were receiving concurrent ITPmedications. Further information regarding the data
from the NEXUS Program and the evolution of the REMS programwill be discussed.
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OBJECTIVES: Little is known about the characteristics of duloxetine patients initi-
ating therapy for chronic lower back pain (CLBP). This study identified demo-
graphic and clinical characteristics associated with initiation of duloxetine versus
other painmedications among CLBP patients.METHODS: Adult CLBP patients who
initiated medication therapy (duloxetine, anticonvulsants, antidepressants, mus-
cle relaxants, non-steroidal anti-inflammatory drugs [NSAIDs], opioids, or benzo-
diazepines) between November 1, 2010-March 31, 2011 were selected frommedical
and pharmacy claims from Medco Health Solutions. Treatment initiation was de-
fined as no pill coverage of themedication over the previous 90 days. The dispense
date of the first initiated medication was set as the index date. Comorbidities and
prior medication use was assessed during the 6 months before the index date.
Multiple logistic regression models were performed to identify predictors of initi-
ating duloxetine versus other pain medication. Separate models were estimated
with Charlson comorbidity index (CCI)  use of selected medications, and individ-
ual comorbidities  number of unique medications, respectively. RESULTS: We
identified 38,943 CLBP patients (mean age 58.0 years; 62.8 % female) who initiated
opioids (36.0%), NSAIDs (21.1%), muscle relaxants (13.6%), benzodiazepines (8.9%),
antidepressants (8.7%), anticonvulsants (7.5%), or duloxetine (4.1%). Patients who
initiated duloxetine had significantly higher CCI and more inpatient stays than
patients who initiated other pain medications except for anticonvulsants. The
regression results showed older patientswere less likely to initiate duloxetine than
anticonvulsants or opioids. Patients with higher CCI weremore likely to initiate on
duloxetine except for anticonvulsants and antidepressants. Prior use of pregabalin,
gabapentin, antidepressants, and benzodiazepines were associated with a higher
likelihood of initiating duloxetine. Patients who had more unique medications,
peripheral vascular disease, or depression were more likely to initiate duloxetine.
CONCLUSIONS: Presence of selected demographic characteristics, comorbidities
and prior use of medications were significant predictors of duloxetine initiation
among CLBP patients.
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OBJECTIVES: The purpose of this study was to identify the demographic and clin-
ical characteristics associated with the initiating dose of duloxetine among pa-
tients with chronic lower back pain (CLBP). METHODS: Medical and pharmacy
claims of CLBP patients who initiated duloxetine were analyzed. Initiation was
defined as no duloxetine coverage in the 90 days preceding the first duloxetine
prescription fill betweenNovember 1, 2010-March 31, 2011, Comorbidities and prior
medication use were assessed during 6 months prior to initiation (the index date).
Multiple logistic regressionmodels were estimated to identify predictors of initiat-
ing 60mg or 60mg versus 60mg, the recommended dose. RESULTS: 1,583 CLBP
patients (mean age 57.3 years; 69.2% female) who initiated duloxetine were iden-
tified. Common comorbidities were hypertension (47.6%) depression (37.2%) and
diabetes (21.1%). Opioids (79.7%) were the most commonly used pain medications
prior to duloxetine initiation, followed by antidepressants (54.6%) and muscle re-
laxants (40.9%). Regression results suggested that, patients 75 years were more
likely to initiate on a dose 60mg (Odds Ratio [OR]: 2.23, 95% confidence interval
[CI]: 1.46-3.38) and less likely to initiate on a dose60mg (OR: 0.39, 95% CI: 0.17-0.90)
than those 18-44 years old. Patients who used duloxetine in 6 months prior were
less likely to start on 60mg (0.64, 95% CI: 0.41-1.00), and more likely to start on
60mg (OR: 2.09, 95% CI: 1.29-3.39). Patients with prior use of opioid (OR: 0.71, 95%
CI: 0.54-0.95) or depression (OR: 0.75, 95% CI: 0.59-0.96) were less likely to initiate on
60mg, whereas patients with rheumatologic disease were more likely to start on
60mg (OR: 2.48, 95% CI: 1.34-4.59). CONCLUSIONS: A majority of CLBP patients
initiated duloxetine at 60mg/day. Presence of selected comorbidities and prior use
of medications were associated with certain initiating doses of duloxetine among
CLBP patients.
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OBJECTIVES: To develop and validate an algorithm enabling the classification of
prophylactic (PPL) vs. on-demand (OD) factor VIII (FVIII) regimens for hemophilia A
(HA) patients in health insurance claims databases, thereby enabling the assess-
ment of these treatment approaches in real-world settings. METHODS: Prescrip-
tion records from two 2010-2011 US specialty pharmacy dispensing databaseswere
used. Males aged 2 years old with a HA diagnosis, 1 prescription for FVIII, no
anti-inhibitor agents ormixed PPL/OD FVIII regimenswere included. Four variables
common to specialty pharmacy and standard claims databases were used to de-
velop the algorithm: age at first observed dispensing (a weight proxy); total units of
FVIII dispensed (TUFVIII); and if TUFVIII data were not available, vial potency (IU/
vial) and number of vials dispensed were used to calculate TUFVIII dispensed (IU/
vial*number of vials dispensed). Different TUFVIII thresholds per age groups 2-12,
13-16, 17-27, and 28 formed the algorithm. Several TUFVIII thresholds for each
age group were iteratively tested over various observation lengths for patients
classified as on PPL (vs. OD) regimen. Each algorithm was assessed against actual
regimens prescribed based on physician notes using sensitivity, specificity, posi-
tive and negative predictive values (PPV & NPV). RESULTS: 445 patients were iden-
tified with 65% on PPL regimens. Patients receiving OD regimens were significantly
older than those receiving PPL regimens (Mean age [years] OD: 24.417.1; PPL:
19.613.0; p0.02). The best-performing algorithm was based on TUFVIII thresh-
olds of 43,920 (age group 2-12), 104,100 (13-16), 139,200 (17-27), and 176,970 (28),
over the first 12months of observation. Sensitivity, specificity, PPV, andNPV of this
algorithm were 0.81, 0.82, 0.89, and 0.71, respectively. CONCLUSIONS: The best-
performing algorithm showed promising performance validity with PPV0.89 for
ascertainment of PPL FVIII regimens in HA patients. Further refinement of the
classification algorithm on larger populations is needed.
PSY65
META-ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE OUTCOMES –
METHODS FOR ENHANCING INTERPRETABILITY OF FINDINGS
Thorlund K1, Walter S1, Johnston B1, Furukawa T2, Guyatt G1
1McMaster University, Hamilton, ON, Canada, 2Kyoto University School of Medicine, Sakyo-ku,
Kyoto, Japan
OBJECTIVES:Todescribe the available approaches for enhancing interpretability of
meta-analyses involving HRQL outcomes. METHODS: Narrative review of the
methodological literature. Application to two illustrative examples-one investigat-
ing the effect of interventions for respiratory rehabilitation in chronic obstructive
pulmonary disease (COPD), and one comparing pain in patients undergoing lapa-
roscopic cholecystectomy receiving dexamethasone or placebo. RESULTS: We
identified 12 approaches in 3 categories: 1) Summary estimates derived from the
pooled SMD: conversion to units of the most familiar instrument, or conversion to
risk difference or odds ratio. These approaches remain vulnerable to differential
variability in populations; 2) Summary estimates derived from the individual trial
summary statistics: conversion to units of the most familiar instrument or to ratio
of means. Both are appropriate complementary approaches to measures derived
from converted probabilities; and 3) Summary estimates derived from the individ-
ual trial summary statistics and established minimally important differences
(MIDs) for all instruments: presentation in MID units or conversion to risk differ-
ence or odds ratio. Risk differences are ideal for balancing desirable and undesir-
able consequences of alternative interventions. CONCLUSIONS: Use of these ap-
proaches may enhance the interpretability and the usefulness of systematic
reviews involving HRQL outcomes.
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OBJECTIVES: To evaluate the Medicaid Analytic Extract (MAX) database for use in
pharmacoepidemiologic research using hemophilia as a test case.METHODS: This
research was conducted using MAX data (years 2000-2004) for 49 states (excluding
AZ) and DC. We identified patients who received recombinant factor VIIa (rFVIIa),
factor VIII inhibitor bypass activity (FEIBA), factor VIII or factor IX or had a diagnosis
code for coagulation defects (ICD-9 286.xx). Use of antihemophilic drugs was iden-
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